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http://dx.doi.org/10.1016/j.ccell.2015.06.004SUMMARYEmerging evidence demonstrates that the DNA repair kinase DNA-PKcs exerts divergent roles in transcrip-
tional regulation of unsolved consequence. Here, in vitro and in vivo interrogation demonstrate that DNA-
PKcs functions as a selective modulator of transcriptional networks that induce cell migration, invasion,Significance
Mechanisms underlying metastatic development remain incompletely defined, and few therapeutic regimens effectively
target the metastatic process. Studies here identify DNA-PKcs as a master driver of pro-metastatic signaling and tumor
metastasis through transcriptional regulation, thus shifting paradigms with regard to DNA-PKcs activity and illuminating
critical functions in humanmalignancy. Preclinical findings are strongly supported by clinical observations that demonstrate
that DNA-PKcs is significantly upregulated in advanced disease and predicts for tumor metastases, recurrence, and poor
survival. Moreover, DNA-PKcs was shown to be highly activated in metastatic tumors, independent of DNA damage indi-
cators. These collective findings transform understanding of DNA-PKcs function, establish clinical relevance, and nominate
DNA-PKcs as a therapeutic target to suppress metastases.
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and metastasis. Accordingly, suppression of DNA-PKcs inhibits tumor metastases. Clinical assessment re-
vealed that DNA-PKcs is significantly elevated in advanced disease and independently predicts for metasta-
ses, recurrence, and reduced overall survival. Further investigation demonstrated that DNA-PKcs in
advanced tumors is highly activated, independent of DNA damage indicators. Combined, these findings
reveal unexpected DNA-PKcs functions, identify DNA-PKcs as a potent driver of tumor progression and
metastases, and nominate DNA-PKcs as a therapeutic target for advanced malignancies.INTRODUCTION
The DNA-dependent protein kinase (DNA-PK) is a serine/threo-
nine protein kinase complex composed of a Ku heterodimer
(Ku70/Ku80) and a catalytic subunit (DNA-PKcs) that plays an
important role in the DNA damage response (DDR) and mainte-
nance of genomic stability. In this context, DNA-PK primarily
mediates ligation of DNA double-strand breaks (DSBs) through
nonhomologous end joining (NHEJ), wherein the Ku heterodimer
recognizes and binds broken DNA ends, facilitating recruitment
and activation of DNA-PKcs (Yoo and Dynan, 1999). Activated
DNA-PKcs phosphorylates and alters the function of factors
that mediate NHEJ, including DNA-PKcs itself and histone
H2AX (gH2AX) (An et al., 2010; Chan et al., 2002). While mecha-
nisms governing DNA-PKcs activity are incompletely defined, it
is clear that DNA-PKcs activation is critical for DNA DSB repair
(Kurimasa et al., 1999; Zhao et al., 2006).
DNA-PKcs expression has been shown to correlate with
decreased therapeutic response to DNA-damaging agents in
multiple cancers, implicating DNA-PKcs-mediated DNA repair
as amechanism for tumor cell survival (Beskow et al., 2009; Bou-
chaert et al., 2012). However, DNA-PKcs has also been linked to
poor prognosis in the absence of DNA-damaging therapies
(Evert et al., 2013;Willmore et al., 2008), suggesting a DDR-inde-
pendent role for DNA-PKcs in human malignancies. Studies
further identified DNA-PKcs as a modulator of cancer-associ-
ated pathways distinct from DNA repair, including hypoxia,
metabolism, inflammatory response, and transcriptional regula-
tion (Goodwin and Knudsen, 2014). Notably, DNA-PKcs was
originally discovered and characterized as part of SP1 transcrip-
tional complexes (Jackson et al., 1990) and as a regulatory
component of transcriptionally poised RNA polymerase II
(RNAPII) (Dvir et al., 1992); accordingly, recent studies revealed
that DNA-PKcs is recruited to active sites of transcription (Ju
et al., 2006). DNA-PKcs can interact with the basal transcrip-
tional machinery (Maldonado et al., 1996) and both binds and
modulates the function of multiple sequence-specific transcrip-
tion factors (e.g., AIRE, p53, and ERG) as well as select nuclear
receptors (including the glucocorticoid, progesterone, estrogen
[ER], and androgen receptors [AR]) (Goodwin and Knudsen,
2014). Recently, a critical link was identified between AR
signaling and DNA-PKcs that underlies the capacity of this ste-
roid hormone receptor to promote DSB repair (Goodwin et al.,
2013; Polkinghorn et al., 2013). Briefly, it was shown that AR
binds to the regulatory locus of PRKDC (the gene encoding
DNA-PKcs) in response to androgen stimulation and DNA dam-
age, thereby inducing PRKDC expression and subsequent DNA-
PKcs activity. This induction proved essential for AR-mediated
DSB repair and cell survival in the presence of genomic insult,
and elevated levels of DNA-PKcs were shown to create a posi-
tive feedback loop by virtue of the established ability of DNA-98 Cancer Cell 28, 97–113, July 13, 2015 ª2015 Elsevier Inc.PKcs to serve as an AR comodulator. These findings provided
the mechanistic basis for clinical observations demonstrating
that suppression of AR activity enhances the response to radio-
therapy (Al-Ubaidi et al., 2013; Warde et al., 2011), concordant
with reports showing that AR suppression dampens expression
of repair factors in prostatic adenocarcinoma (PCa) (Al-Ubaidi
et al., 2013; Warde et al., 2011), and illustrated the significance
of AR-DNA-PKcs interplay in PCa. Given the potential implica-
tions of DNA-PKcs-mediated transcriptional activity in human
malignancies, it was imperative to discern the molecular basis
of DNA-PKcs function and the contribution of DNA-PKcs-medi-
ated transcriptional regulation on tumor phenotypes.
RESULTS
DNA-PKcs Interacts with AR and Is Recruited to Sites of
AR Action
Because DNA-PKcs is induced by AR activity and functions as
an AR coactivator in advanced PCa that can bypass anti-
androgen therapy (castration-resistant PCa, CRPC), CRPC
models were selected to interrogate DNA-PKcs-mediated tran-
scriptional regulation. PCa depends on AR activity for growth
and progression, and therapies that suppress AR activity
through ligand deprivation are the first line of intervention for
metastatic disease. Although effective, tumors ultimately recur,
almost invariably through restoration of AR activity (Knudsen
and Scher, 2009). Thus, discerning the impact of DNA-PKcs on
AR function in CRPC is of translational relevance. Consistent
with identification of PRKDC and XRCC6 as androgen-regulated
genes in CRPC (Al-Ubaidi et al., 2013; Goodwin et al., 2013), hor-
mone deprivation decreased DNA-PKcs S2056 phosphorylation
(indicative of decreased activity; Chen et al., 2005) along with
total DNA-PKcs and Ku70 levels (Figure 1A). As such, studies
assessing the function of DNA-PKcs as a transcriptional regu-
lator were performed in hormone-proficient conditions. Loci
explored initially focused on gene regulatory elements governed
by AR and ERG in PCa cells, as DNA-PKcs was implicated as a
modulator of both factors. As predicted, chromatin immunopre-
cipitation (ChIP) analysis revealed AR occupancy at two well-
characterized loci (KLK3/PSA and TMPRSS2 enhancers), but
not at thepromoter of theERG-regulated genePLA1A (Figure 1B,
left). DNA-PKcs was detected at all three regions (Figure 1B,
right), but not in the control region, showing specificity of DNA-
PKcs binding (Brenner et al., 2011). In response to DHT, AR
was recruited to each AR regulatory site within 30 min, with
maximum occupancy at 16 hr post-treatment (Figure 1C, top
left; Figure S1A). In contrast, DNA-PKcs recruitment was de-
layed (6 hr post-treatment) at AR regulatory regions with
maximum occupancy at 16 hr (Figure 1C, top right; Figure S1A),
and unchanged at PLA1A, demonstrating specificity of the DNA-
PKcs response to hormone stimulation (Figure 1C, top). The AR
coregulator p300 was enriched 30 min post-DHT, followed by
RNAPII binding (3–6 hr) at the AR regulatory loci, while neither
was enriched at the PLA1A promoter in response to DHT (Fig-
ure 1C, bottom; Figure S1A), suggesting that DNA-PKcs binding
facilitates coactivator function and potentiates transcriptional
activation. DNA-PKcs levels were not significantly enriched after
DHT treatment at these early time points (Figure S1B). Notably,
DNA-PKcs detection was abrogated at all three loci by
siRNA-mediated depletion (Figure S1C), but was specifically un-
detected at AR-regulated loci after treatment with the AR antag-
onist MDV3100 (Figure S1D). Combined, these findings suggest
that DNA-PKcs is recruited to sites of AR function in response to
AR and initiating p300 occupancy, facilitating active transcrip-
tion. The impact of DNA-PKcs recruitment was determined in
parallel. PLA1A was not induced in response to DHT, and while
significant induction of both KLK3/PSA and TMPRSS2 was
observed 3 hr post-DHT (Figure 1D), maximum induction was
not observed until after peak recruitment of AR and DNA-
PKcs. Further analyses revealed that AR and DNA-PKcs are
found in complex, and that the interaction is not further enriched
by exogenous DHT (Figure 1E). The AR-DNA-PKcs interaction is
not dependent on DNA binding, because pre-addition of
ethidium bromide did not disrupt the complex (Figure 1F), but
did result in dismissal of Ku70, as expected (Brenner et al.,
2011) (Figure S1E). Further, co-immunoprecipitation in 22Rv1
cells (which contain full-length AR and an AR splice variant,
AR-V7, lacking the ligand binding domain (LBD); Guo et al.,
2009) revealed DNA-PKcs interaction with AR-V7 (Figure S1F),
suggesting that DNA-PKcs can bind AR-V7-containing com-
plexes; in contrast, in vitro interaction between Ku70 and AR
was mapped to the AR LBD (Mayeur et al., 2005). Finally,
DNA-PKcs activity was not required for AR interaction but is
important for AR function, as a highly selective DNA-PKcs inhib-
itor, NU7441 (Zhao et al., 2006) (Figures S1G and S1H) did not
suppress complex formation but decreased DHT-stimulated
AR activity (Figure S1I). In sum, these findings reveal that DNA-
PKcs is found in complex with AR and facilitates AR-dependent
transcriptional transactivation.
DNA-PKcs Is a Selective Effector of Transcriptional
Networks
Given the impact of DNA-PKcs on AR, subsequent studies were
directed at identifying the totality of DNA-PKcs mediated tran-
scriptional networks. Initial gene expression analyses were per-
formed in CRPC cells either depleted of DNA-PKcs or treated
with NU7441 (Figure 2A, left); as shown, the siPRKDC pool sup-
pressed DNA-PKcs expression, whereas NU7441 had no effect
on DNA-PKcs levels, and neither affected Ku70 expression (Fig-
ure 2A, right). Genes up- or downregulated by >1.5-fold were
selected for further analysis (Figure 2B). For both manipulations,
the number of genes downregulated far exceeded those that
were upregulated, suggesting that DNA-PKcs primarily posi-
tively regulates transcriptional events. Comparison between
groups demonstrated that DNA-PKcs depletion results in
overlapping but distinct effects as compared to enzymatic inhi-
bition. Tominimize potential off-target effects of NU7441, subse-
quent analyses primarily focused on transcriptional alterations
induced by DNA-PKcs knockdown. Gene Set Enrichment Anal-
ysis (GSEA) and associated motif analysis revealed significantenrichment of genes regulated by MAZ, MYC, and the known
DNA-PKcs-interacting partner SP1, validating the concept that
DNA-PKcs modulates a select subset of transcriptional net-
works (Figure 2C). Gene ontology (GO) analysis demonstrated
that genes sensitive to DNA-PKcs associate with distinct biolog-
ical processes, including transcription and regulation of gene
expression, further supporting a role for DNA-PKcs in gene regu-
lation (Figure 2D). Combined, these findings begin to define the
cellular consequence of DNA-PKcs-mediated transcriptional
regulation and demonstrate that DNA-PKcs selectively governs
transcriptional networks.
DNA-PKcs and AR Cooperate to Suppress UGT Enzyme
Expression in CRPC
Numerous metabolic and hormone pathways of potential clinical
impact in PCa were upregulated by DNA-PKcs depletion (Fig-
ure 3A), including steroid hormone biosynthesis, which exhibited
upregulation of UGT glycosyltransferases (Figure 3B). UGT en-
zymes catalyze transfer of glucuronic acid to small molecules
(including androgens), facilitating metabolism and excretion
(Rowland et al., 2013). In the prostate, local androgen inactiva-
tion occurs when DHT is directly modified by glucuronidation
or is metabolized to 5a-androstane-3a-diol (3a-diol) and andros-
terone (AST), which are then glucuronidated by UGT2B15 and
UGT2B17. Consistent with previous reports suggesting that
these genes are also AR regulated (Bao et al., 2008), AR occu-
pied the proximal promoters of both UGT2B15 and 2B17, with
a modest but significant increase observed upon DNA-PKcs
depletion (Figures 3C and 3D, left). DNA-PKcs co-occupied
these sites (Figure 3D, right), suggesting that negative regula-
tion by DNA-PKcs is direct. DNA-PKcs depletion resulted in
increased UGT2B15 and 2B17 expression, underscoring the
impact of DNA-PKcs on this pathway (Figure 3E). Previous
studies showed that DNA-PKcs negative transcriptional regula-
tion can be mediated through NCoR and SMRT (Jeyakumar
et al., 2007; Yu et al., 2006), and both were both enriched at
the UGT2B15 and 2B17 promoters. Corepressor binding was
significantly reduced by DNA-PKcs depletion (Figure S2A), but
not after kinase inhibition (Figure S2B), suggesting that DNA-
PKcs occupancy (but not activity) is needed for NCoR and
SMRT residence. As expected, DHT stimulation decreased
UGT2B15 and 2B17, which was partially reversed by DNA-
PKcs depletion (Figure S2C), consistent with a role for DNA-
PKcs in negative regulation. Because UGT2B15 and 2B17
protein accumulation was also enhanced after DNA-PKcs deple-
tion (Figure 3F), the impact of DNA-PKcs depletion on DHT me-
tabolites was quantified by high-pressure liquid chromatography
(HPLC) (Figure S2D). Cells depleted of DNA-PKcs trended
toward decreased overall levels of free DHT, but did not reach
statistical significance (Figure 3G, left) and there was no impact
on G-DHT (Figure 3G, right) or G-AST (Figure S2E), suggesting
that elevated UGT2B15 and 2B17 is not sufficient to indepen-
dently alter hormone metabolism. Similar regulation of other
UGT enzymes after DNA-PKcs depletion (Figure 3B) argues
against functional redundancy affecting DHT levels. The overall
findings are of translational significance, because UGT2B15
and 2B17 are being developed as prognostic markers and
therapeutic targets in PCa (Grosse et al., 2013), and the mecha-






Figure 1. DNA-PKcs Binds AR and Is Recruited to Sites of AR Action
(A) C4-2 cells were treated with ADT (CSS) for 24 hr and immunoblot analysis for phospho-S2056 DNA-PKcs, total DNA-PKcs, and Ku70 was performed.
(B and C) C4-2 cells in hormone-proficient media were (B) harvested for ChIP-qPCR analysis and percent (input) occupancy of AR (left) or DNA-PKcs (right)
reported or (C) treated with 10 nM DHT and harvested for ChIP-qPCR analysis with percent (input) occupancy of AR, DNA-PKcs, p300, or RNPII set relative to
control at each time point.
(legend continued on next page)
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Figure 2. DNA-PKcs Selectively Affects Gene Expression in CRPC
(A) RNA harvested from C4-2 cells depleted of DNA-PKcs or treated with 1 mM NU7441 (DNA-PKcsi) for 24 hr was analyzed by microarray analysis (left).
Immunoblot of phospho-S2056 DNA-PKcs, total DNA-PKcs, and Ku70 after knockdown or NU7441 treatment (right).
(B) Genes identified as upregulated (left) or downregulated (right) byR1.5-fold compared to untreated.
(C and D) GSEA motif (left) or GO (right) analyses of all genes altered at least 1.5-fold after DNA-PKcs knockdown.relevance, a cohort of 232 patients with high-risk localized PCa
was examined, wherein it was observed that both UGT2B15
(correlation coefficient 0.28, p < 0.0001) and UGT2B17 (corre-
lation coefficient 0.38, p < 0.0001) expression strongly nega-
tively correlated with DNA-PKcs (Figure 3H), supporting the
concept that DNA-PKcs suppresses expression of UGT en-
zymes in human tumors. Further analysis in response to
NU7441 confirmed the function of DNA-PKcs as a selective(D) C4-2 cells were treated with 10 nM DHT and relative transcript expression an
(E and F) C4-2 cells were treated with 10 nM DHT for 6 hr and co-immunopre
bromide.
Data are reported as mean ± SD. *p < 0.05 **p < 0.01. See also Figure S1.negative regulator of transcription (Figure S2F). On balance,
these findings identify gene networks that are negatively regu-
lated by DNA-PKcs and identify DNA-PKcs as a key modulator
of the UGT enzyme cancer-associated pathway.
DNA-PKcs Promotes Pro-metastatic Signaling
Whereas DNA-PKcs negatively regulates steroid regulated
pathways, the majority of DNA-PKcs-mediated transcriptionalalyzed as normalized to GAPDH mRNA at each time point.
cipitation performed in the absence (E) or presence (F) of 50 mg/ml ethidium







Figure 3. DNA-PKcs and AR Cooperate to Suppress UGT Enzyme Expression in CRPC
(A) GSEA KEGG pathway analysis of genes upregulated byR1.5-fold compared to control after DNA-PKcs knockdown.
(B) Heatmap of transcript change of UGT enzymes in the DNA-PKcs knockdown groups.
(C and D) C4-2 cells depleted of DNA-PKcs were harvested for ChIP-qPCR analysis and percent (input) occupancy of AR (D, left) or DNA-PKcs (D, right) at
indicated loci reported. TSS, transcriptional start site.
(E and F) CRPC cells depleted of DNA-PKcs were subject to either qPCR (E, C4-2 left, 22Rv1 right) or immunoblot (F, C4-2) analysis.
(G) Free (left) and G-DHT (right) levels in C4-2 cells depleted of DNA-PKcs were determined by HPLC.
(H) Tumor samples were profiled for mRNA expression of DNA-PKcs, UGT2B15, and UGT2B17 and correlation coefficients determined.
Data are reported as mean ± SD. *p < 0.05 **p < 0.01. See also Figure S2.
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effects support coactivator functions. KLK3/PSA, TMPRSS2,
and other well-characterized PCa-relevant AR-regulated genes
(Goodwin et al., 2013; Mayeur et al., 2005) were generally
reduced after DNA-PKcs depletion (Figure S3A), as expected.
Analysis of genes downregulated after DNA-PKcs depletion (Fig-
ure 4A) or NU7441 (Figure S3B) revealed enrichment in pathways
associated with cancer progression (Figure 4B; Figure S3C),
prominently associated with cell migration and invasion. The
focal adhesion gene signature was markedly suppressed by
DNA-PKcs depletion (Figure 4C) or NU7441 (Figure S3D). Fac-
tors in the focal adhesion signature have previously been impli-
cated in PCa progression and metastasis, including PREX1
(GEF for Rac1) (Qin et al., 2009), ROCK2 (effector of Rho
signaling) (Kroiss et al., 2014), Integrin b4 (ITGB4, which regu-
lates matrix organization through the Rac1 pathway) (Yoshioka
et al., 2013), and VAV3 (GEF for Rho and Rac1) (Lyons and Burn-
stein, 2006). Expression of each was significantly reduced in
hormone-therapy (HT)-sensitive cells (LNCaP), CRPC cells with
limited metastatic potential (C4-2), and AR-negative CRPC cells
with high metastatic potential (PC3-ML) after DNA-PKcs deple-
tion (Figure 4D) or 24 hr inhibitor treatment (Figure S3E), with
the exception of ITGB4 in PC3-ML cells, which was not signifi-
cantly altered, suggesting a possible role for AR in regulation.
As expected, ATM (ataxia telangiectasia mutated) levels were
diminished after DNA-PKcs depletion but not after DNA-PKcs in-
hibition (Goodwin et al., 2013; Peng et al., 2005) (Figure 4E). ATM
depletion did not significantly alter expression of the identified
genes (Figure 4F), suggesting that these transcriptional events
are not ATM mediated. Observations were confirmed using
alternative strategies to deplete DNA-PKcs or a second highly
selective DNA-PKcs inhibitor NU7026 (the lead compound in
generation of NU7441) (Veuger et al., 2003) (Figure S3F). Kinetic
analysis revealed a time-dependent decrease in target gene
expression 6 hr after treatment (Figure S3G), suggesting direct
impact of DNA-PKcs on transcriptional regulation. Consonantly,
DNA-PKcs binds to the proximal promoter regions containing
motifs of known DNA-PKcs associated transcription factors
for PREX1 (Wong et al., 2011), ROCK2, and ITGB4 (Drake
et al., 2010) (Figure 4G). Treatment with MDV3100 modestly
decreased expression of ROCK2 and ITGB4 (Figure S3H), sug-
gesting that AR is not universally required for DNA-PKcs-medi-
ated regulation of genes in this pathway. DNA-PKcs occupancy
was further examined at the proximal promoter regions of
PREX1, ROCK2, and ITGB4 after MDV3100 treatment or
depletion of SP1 or MAZ, the top motifs identified. MDV3100
decreased DNA-PKcs occupancy at the ROCK2 and ITGB4 pro-
moters but not at the PREX1 promoter, consistent with the tran-
script data (Figure S3I, left). SP1 depletion resulted in remarkable
reduction in DNA-PKcs occupancy at the PREX1 promoter
(consistent with PREX1 being regulated by SP1; Wong et al.,
2011) and modest but significant reduction in occupancy at
both the ROCK2 and ITGB4 promoters (Figure S3I, middle),
whereas MAZ depletion produced a significant reduction in
DNA-PKcs occupancy at the ITGB4 promoter, modest reduction
in occupancy at the PREX1 promoter (not statistically signifi-
cant), and no change at the ROCK2 promoter (Figure S3I, right).
These studies reveal that DNA-PKcs-mediated expression is
differentially regulated by transcription factors whose activities
are modulated by DNA-PKcs. Decreased transcript expressionresulted in reduced protein levels for the factors analyzed (Fig-
ure 4H), identifying DNA-PKcs as a positive regulator of metasta-
tic signaling. PREX1, ROCK2, ITGB4, and VAV3 all interact with
Rho GTPases that influence cell motility and invasion (Cook
et al., 2014). DNA-PKcs depletion or inhibition decreased Rho
and Rac1 activity (Figure 4I; Figure S3J). Depletion of VAV3
strongly reduced activated Rho and moderately suppressed
Rac1 activity, whereas depletion of PREX1 diminished activated
Rac1 with minimal effects on Rho (Figure S3K), demonstrating
importance in DNA-PKcs mediated regulation of Rac/Rho
signaling pathways, although other GEFsmay be involved. Com-
bined, these findings identify DNA-PKcs as a direct and positive
regulator of Rac/Rho function and pro-metastatic pathways.
DNA-PKcs Promotes Metastatic Phenotypes
Given the impact of DNA-PKcs on pro-metastatic signaling, the
consequence for metastatic potential was determined. Deple-
tion of DNA-PKcs resulted in decreased migration in all models
(Figure 5A, left) and invasion in the CRPC models (Figure 5A,
right). Consonantly, DNA-PKcs inhibition suppressed migration
(Figure 5B, top) and invasion (Figure 5B, bottom) in all models.
Both C4-2 and PC3-ML are CRPC lines capable of proliferating
in the absence of hormone, and proliferation of LNCaP cells in
hormone-deficient media was not significantly altered after
DNA-PKcs inhibitor treatment (Figure S4A). The ROCK2 inhibitor
reduced migration and invasion similar to that observed
with NU7441 (Figure 5B). Combination of the DNA-PKcs and
ROCK2 inhibitors resulted in modest but significant decreases
in migration in C4-2 and PC3-ML cells and further suppressed
invasion in all models compared to either inhibitor alone, sug-
gesting that DNA-PKcs regulates migration and invasion
through pathways in addition to Rho signaling. Furthermore,
cells depleted of UGT2B15 or 2B17 failed to demonstrate signif-
icant changes in migratory or invasive potential (Figure S4B),
suggesting that DNA-PKcs effects on metastatic phenotypes
are independent from effects on metabolism. In sum, these find-
ings establish DNA-PKcs as a positive regulator of gene expres-
sion events that induce migration and invasion.
DNA-PKcs Inhibition Delays Formation of Metastases
In Vivo
To determine the impact of DNA-PKcs on metastatic develop-
ment in vivo, PC3-ML cells expressing luciferase were pre-
treated for 48 hr with NU7441 or vehicle and injected into the
tail veins of severe combined immunodeficiency (SCID) mice.
Mice were treated every 24 hr (5 days/week) with 25 mg/kg
NU7441 or vehicle, and tumor formation monitored by live imag-
ing (Figure S5A). Parallel studies wherein cells were maintained
in culture revealed no significant differences in cell number or
viability between the cohorts (Figure S5A). Whereas robust
metastases were observed in the control arm, total tumor burden
observed in the DNA-PKcs inhibitor-treated cohort was signifi-
cantly reduced, demonstrating that DNA-PKcs inhibition delays
formation of productive metastases in vivo (Figure 6A). These
findings provide evidence linking DNA-PKcs enzymatic activity
to development of metastases.
To further investigate the impact of DNA-PKcs, crossover
studies were performed wherein animals in the control arm







Figure 4. DNA-PKcs Promotes Pro-metastatic Signaling
(A) GSEA KEGG pathway analysis of genes downregulated byR1.5-fold compared to control after DNA-PKcs knockdown.
(B and C) Heatmap of transcript change of pathways in cancer (B) or focal adhesion (C) pathway genes in the DNA-PKcs knockdown groups.
(D) C4-2 and PC3-ML cells in hormone-proficient or LNCaP cells in hormone-deficient media treatedwith siDNA-PKcs or siControl were subject to qPCR analysis
with control dataset to one for each cell line.
(E) Immunoblot analyses of C4-2 cells depleted of DNA-PKcs or treated with 1 mM NU7441.
(F) C4-2 cells depleted of ATM were harvested for qPCR analysis with relative expression of indicated transcripts analyzed and normalized to GAPDH.
(legend continued on next page)
104 Cancer Cell 28, 97–113, July 13, 2015 ª2015 Elsevier Inc.
switched to the NU7441 arm; conversely, 3 mice randomly
selected from the NU7441 arm (denoted 4, 5, and 6) were
removed from treatment. After 2 weeks, animals moved from
control to NU7441 failed to show reductions in tumor burden
at established sites of metastases, consistent with the concept
that DNA-PKcs inhibitors block development of productive me-
tastases rather than suppressing tumor growth (Figure 6B).
Conversely, animals released fromNU7441 incurred dramatic in-
duction of metastatic burden, with the tumor-doubling time
reduced by 50%–90% (Figure 6C), suggesting that resurgent
DNA-PKcs activity drives metastatic development. Mice not
selected for crossover were continued on study, and total tumor
burden remained suppressed in the NU7441 cohort but not the
control arm (Figure S5B). Proliferation rates of the metastatic
lesions in the lungs were similar in both crossover cohorts (Fig-
ure S5C), again suggesting that tumor changes in animals
released from inhibitor illustrate the impact of DNA-PKcs on
metastases and not proliferation, although it is possible that
NU7441 treatment of large tumors in the crossover may be
less effective due to tumor size. Experiments using AR-positive
22Rv1 cells also demonstrated a significant decrease in overall
metastatic tumor burden (Figure S5D), although this model is
less aggressive in developing metastatic lesions. Combined,
these findings clearly reveal that DNA-PKcs induces tumor
metastases in vivo, confirming the importance of DNA-PKcs
regulated pathways in metastatic development.
To further characterize the impact of DNA-PKcs on metastatic
development in AR-positive but aggressive models of sponta-
neous metastasis, CASP-NPK-YFP tumor cells (Aytes et al.,
2013) were engrafted into nude mice. Post-engraftment
(5 days), mice were randomized for treatment with 25 mg/kg
NU7441 or vehicle (5 days/week for 30 days) (Figure S5E).
DNA-PKcs suppression decreased overall tumor burden (Fig-
ure 6D), although primary tumor weight was not significantly
altered between the treatment groups (Figure S5F); in contrast,
significant reduction of metastatic lung lesions was observed
in the inhibitor treated cohort, with a less pronounced but similar
trend in liver metastases (Figure 6E). Finally, analysis of tumors
harvested at sacrifice revealed significant decrease in transcript
expression of Prex1, Rock2, Itgb4, and Vav3 (Figure 6F), demon-
strating that DNA-PKcs modulates expression of these four met-
astatic genes and promotes development of metastatic lesions
in vivo. Thus, DNA-PK promotes metastatic signaling and tumor
metastases in both AR-positive and AR-negative cancers.
DNA-PKcs Inhibition Modulates Expression of
Pro-metastatic Factors in Primary Human Tumors
Transcriptional regulatory functions of DNA-PKcs on pro-meta-
static factors were further assessed using an ex vivo culture sys-
tem of primary human PCa, in which tissue obtained immediately
upon surgical resection can be subdivided, cultured, and sub-
jected to targeted therapy as previously described (Centenera
et al., 2013) (Figure 7A). Explant specimens retain the complex(G) C4-2 cells harvested for ChIP-qPCR analysis and percent (input) occupancy
(H) C4-2 cells depleted of DNA-PKcs or treated with 1 mM NU7441 for 48 hr wer
(I) C4-2 cells depleted of DNA-PKcs or treated with 1 mMNU7441 for 48 hr were an
immunoblot.
Data are reported as mean ± SD. *p < 0.05, **p < 0.01. See also Figure S3.3D structure and microenvironment of the original tumor and
can be used for clinical assessment of targeted agents (Cente-
nera et al., 2013; Schiewer et al., 2012). Although major alter-
ations in histoarchitecture were not observed after exposure to
NU7441 (Figure 7B), DNA-PKcs inhibition effectively suppressed
expression of PREX1, ROCK2, ITGB4, and VAV3 (Figure 7C). In
sum, these findings confirm that DNA-PKcs inhibition regulates
expression of pro-metastatic factors in primary human tumors.
DNA-PKcs Expression and Activity Predicts Clinical
Disease Recurrence and Metastatic Development
Finally, the prognostic impact of DNA-PKcs in the clinical setting
was investigated. A cohort of 232 patients with high-risk local-
ized PCa was examined to assess the relevance of DNA-PKcs
expression on outcomes following prostatectomy. As shown,
elevated DNA-PKcs conferred reduced freedom from biochem-
ical recurrence (Figure 8A, p = 0.050, hazard ratio [HR] = 1.5), and
dramatically worse freedom from metastatic progression (Fig-
ure 8B, p = 0.0004, HR = 2.4), PCa-specific survival (Figure S6A,
p = 0.001, HR = 2.8), and overall survival (Figure 8C, p < 0.0002,
HR = 3.1). These results were comparable to the HRs of high
Gleason score for these same outcomes (biochemical recur-
rence: HR = 1.3, p = 0.1; metastasis: HR = 2.2, p = 0.0007;
PCa-specific survival: HR = 4.4, p < 0.0001; overall survival:
HR = 2.2, p = 0.003). Because Gleason score is one of the stron-
gest known predictors for aggressive disease (Van der Kwast,
2014), these data illustrate the potent role of DNA-PKcs in pro-
moting lethal PCa. Further, analysis of DNA-PKcs correlated
genes showed significant enrichment in the AR pathway (Fig-
ure 8D, p < 0.0001, normalized enrichment score [NES] =
2.673), the AR transcription factor pathway (Figure S6B, p <
0.0001, NES = 2.474), MAZ targets (Figure 8E, p < 0.0001,
NES = 1.689), SP1 targets (Figure 8F, p < 0.0001, NES =
1.758), and the focal adhesion pathway (Figure 8G, p < 0.0001,
NES = 1.635), thus validating the preclinical findings. As ex-
pected, multiple pathways associated with DDR were also
enriched (Table S1). DNA-PKcs was significantly positively
correlated with AR, SP1, andMAZ expression in the clinical sam-
ples (Figure S6C, correlation coefficients of 0.68, 0.77, and 0.70,
respectively, all p < 0.0001), further supporting the functional
connectivity. Finally, elevated UGT2B15, but not 2B17, was
associated with decreased freedom from metastases (Fig-
ure S6D). These findings, compared with previous reports (Mit-
siades et al., 2012; Paˆquet et al., 2012), provide the basis for
future studies directed at discerning the potentially divergent
roles of UGT2B15 and 2B17 in CRPC progression. These obser-
vations identify DNA-PKcs asmarkedly upregulated in advanced
disease, confirm the link between DNA-PKcs and metastatic
signaling, and strongly support the contention that DNA-PKcs
mediated transcriptional regulation is a major effector of lethal
tumor phenotypes.
To further interrogate the link between DNA-PKcs and metas-
tasis, an independent cohort was analyzed wherein DNA-PKcsof DNA-PKcs at the indicated regulatory regions.
e subject to immunoblot analysis.
alyzed for activated (GTP-bound) Rho and Rac1 by column binding followed by
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Figure 5. DNA-PKcs Induces Metastatic Phenotypes
(A) Cells depleted of DNA-PKcs were seeded into hormone-deficient media and allowed to migrate (left) or invade through matrigel (right) toward hormone-
proficient media.
(B) Cells pre-treated with 1 mM NU7441, SLx-2119 or combination of both for 24 hr were seeded into hormone-deficient media and allowed to migrate for 24 hr
(top) or invade through Matrigel for 72 hr (bottom) toward hormone-proficient media.
Data are reported as mean ± SD. *p < 0.05, **p < 0.01 compared to control unless otherwise indicated. See also Figure S4.phosphorylation was quantified by phospho-proteomic analyses
of fresh clinical specimens from organ confined, treatment naive
PCa versusmetastatic CRPC.Multiple DNA-PKcs residues were106 Cancer Cell 28, 97–113, July 13, 2015 ª2015 Elsevier Inc.hyper-phosphorylated in metastatic CRPC, including Thr2609,
an autophosphorylation residue also reported to be phosphory-
lated by ATM (Chen et al., 2007) and indicative of enzymatic
activation (Chan et al., 2002) (Figure 8H; Table S2). These find-
ings reveal that DNA-PKcs is not only present, but also highly
active in late stage, metastatic CRPC. In contrast, analysis
of gH2AX, a marker of DNA DSBs, in metastatic tissues
demonstrated no detectable change in phosphorylation levels
compared to treatment-naive tissues (Figure 8H), suggesting
that the heightened DNA-PKcs activation is not the result (or
readout) of elevated DNA damage in metastatic tissues. Com-
bined, these clinical analyses reveal that DNA-PKcs expression
predicts for disease recurrence and DNA-PKcs phosphorylation
suggests significant activation in metastatic tissues independent
of heightened damage response, validating the preclinical evi-
dence that DNA-PKcs is a master regulator of transcriptional
events driving disease progression and development of meta-
static lesions (Figure 8I).
DISCUSSION
Understanding mechanisms contributing to tumor progression
and metastatic development is crucial for development of effec-
tive therapeutic strategies targeting advanced cancers. This
study identifies DNA-PKcs as a key contributor to metastatic
progression, mediated through transcriptional regulation. Key
findings reveal that (1) DNA-PKcs interacts with AR and is
recruited to regulatory loci of AR target genes upon DHT stimu-
lation, facilitating transcriptional activation; (2) DNA-PKcs selec-
tively modifies transcriptional networks associated with tumor
progression, and is recruited to loci regulated by DNA-PKcs-
associated transcription factors; (3) UGT enzymes are negatively
regulated by DNA-PKcs, implicating DNA-PKcs in pathways
associated with therapeutic relapse; (4) DNA-PKcs positively
regulates a transcriptional network that promotes pro-metasta-
tic signaling, resulting in DNA-PKcs-induced tumor cell migra-
tion and invasion; (5) pharmacological DNA-PKcs inhibition
prevents formation of metastases in vivo; (6) analyses of clinical
specimens reveal that DNA-PKcs is elevated and highly active in
advanced disease, distinct from marks of DNA damage; and
(7) DNA-PKcs dysregulation is strongly associated with develop-
ment of distant metastases and reduced survival. In sum, these
findings strongly support a model wherein the transcriptional
regulatory functions of DNA-PKcs induce a pro-metastatic
signaling program that drives tumor metastases and lethal dis-
ease. These studies not only define DNA-PKcs as a metastatic
driver and a putative biomarker of disease progression, but
also nominate DNA-PKcs as a therapeutic target.
Data here are consistent with literature identifying DNA-PKcs
as associated with sequence-specific transcription factors.
Recent studies identified DNA-PKcs in ER/coregulator com-
plexes (Foulds et al., 2013) and as an AR coactivator (Goodwin
et al., 2013; Mayeur et al., 2005). This study provides direct
insight into themechanism of coordinated transcriptional regula-
tion between AR and DNA-PKcs, wherein DNA-PKcs is recruited
with delayed kinetics to sites of AR function, and is required
for maximum AR activity. Among the AR target genes sensitive
to DNA-PKcs regulation, TMPRSS2 was recently shown to
promote metastasis (Lucas et al., 2014), providing another
mechanism by which DNA-PKcs may modulate metastatic
development. Ongoing investigation is directed at discerning
the impact of DNA-PKcs on the chromatin microenvironmentsurrounding AR and DNA-PKcs binding. The studies herein iden-
tify DNA-PKcs as an AR coregulator, supporting a role for DNA-
PKcs in cancer-relevant transcriptional events.
Consistent with these findings, emerging evidence links DNA
repair factors to transcriptional regulation. Initial studies reported
that recruitment of DDR machinery was primarily the result of
transient, site-specific DSBs required for transcriptional activa-
tion (Ju et al., 2006). Furthermore, the gene rearrangements
observed in PCa can result from fusion events in transcriptional
hubs bringing together distant chromosomal regions (Tomlins
et al., 2005), suggesting that DNA repair capacity is needed at
sites of active transcription. However, recent findings suggest
that repair factors hold transcriptional regulatory functions inde-
pendent of damage response, as exemplified by PARP1, a DNA
repair factor with roles in transcriptional regulation whose func-
tions can be segregated (Steffen et al., 2014). Whereas the
effects of DNA-PKcs on transcriptional activation reported here
occurred in the absence of exogenous damage, it is possible
that transcription-associated DNA breaks may contribute to
observed DNA-PKcs activation. Irrespective of the means of
activation, the findings herein demonstrate that DNA-PKcs inter-
acts with known transcriptional modulators, binds to sites of
transcriptional activation, and selectively engages a transcrip-
tional network of strong cancer relevance.
The concept that DNA-PKcs suppresses UGT2B15 and 2B17
enzyme expression at least partially through NCoR and SMRT
provides insight into how this PCa-relevant pathway is governed
(Chouinard et al., 2006). Deregulation of androgen metabolism
contributes to PCa progression (Chang et al., 2013) and may
contribute to metastatic development (Mitsiades et al., 2012).
Gene suppressive roles for DNA-PKcs have previously been re-
ported (Hill et al., 2011; Jeyakumar et al., 2007; Yu et al., 2006),
suggesting that DNA-PKcs-mediated transcriptional repression
is not unique. Although AR is required for basal expression of
both UGT2B15 and 2B17, stimulation with androgen results in
gene downregulation (Bao et al., 2008), suggesting that resur-
gent AR signaling in CRPC may have a role in DNA-PKcs-medi-
ated transcriptional repression of UGT enzyme expression.
Factors influencing UGT expression in non-prostatic tissues
include NRF and SP1 (Mackenzie et al., 2010), and influence
on these factors may contribute to the impact of DNA-PKcs.
Because UGT2B15 and 2B17 are being evaluated as pharmaco-
logic targets for PCa management (Grosse et al., 2013), the
identified link to DNA-PKcs may prove important in designing
therapeutic regimens.
Identification of DNA-PKcs as a master regulator of pro-meta-
static signaling complements previous studies linking the kinase
to cancer-associated transcription factors (Brenner et al., 2011).
The top scoring pathway for positively regulated DNA-PKcs
genes is focal adhesion, hallmarked by factors that contribute
to progression of multiple malignancies. Although the mecha-
nisms regulating ITGB4, PREX1, ROCK2, and VAV3 expression
are not well defined, previous reports identified binding sites
for DNA-PKcs interacting transcription factors within regulatory
regions. Moreover, promoter motif analysis of genes sensitive
to DNA-PKcs depletion revealed enrichment for binding sites
of DNA-PKcs interacting transcription factors (e.g., SP1, LEF1,
and MYC). The AR binding sequence was not among the top




Figure 6. DNA-PKcs Inhibitors Delay Formation of Metastases In Vivo
(A) Mice were injected with luciferin 31 days post-tail vein injection of PC3-ML cells and imaged using the IVIS imaging systemwith total luciferase signal reported
(left) and representative images shown (right). Indicated mice were selected for crossover studies.
(B and C) Mice were injected with luciferin and imaged for 2 weeks after initiation of crossover studies with total luciferase signal reported (left), representative
images shown (middle), and average doubling times pre- and post-crossover calculated.
(D) CASP-NPK-YFP tumors were measured twice weekly for 30 days after initiation of treatment (endpoint for survival was the predefined tumor volume of
1.5 cm3) with volumes calculated using the formula volume = (width)2 3 length/2.
(legend continued on next page)
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Figure 7. DNA-PKcs Inhibition Modulates Expression of Pro-metastatic Factors in Primary Human Disease
(A) Schematic of explant assay, adapted from Schiewer et al., 2012.
(B) Representative images of explant tissues treated with control or 1 mM NU7441 and stained with hematoxylin & eosin.
(C) Explant tissues were harvested on day 6 for qPCR analysis with indicated transcripts set relative to GAPDH.
Data are reported as mean ± SD. *p < 0.05.response elements (AREs) are present at only 40% of known
AR-binding sites, and AR primarily regulates transcription from
enhancers (Yu et al., 2010). However, one of the top motifs iden-
tified was ELK1, an ETS domain factor required for expression of
a major subset of AR target genes (Patki et al., 2013), supporting
the finding that DNA-PKcs modulates AR-dependent transcrip-
tion. Characterization of genome-wide DNA-PKcs occupancy
combinedwith identification of the DNA-PKcs-associated prote-
ome is a focus of current studies and will help to completely
define partners of DNA-PKcs used to selectively modulate
transcription.
A major consequence of DNA-PKcs-mediated transcriptional
regulation is tumor metastasis, and the Rho/Rac pathway was
identified as a critical effector of DNA-PKcs activity. Previous
studies established a role for Rho/Rac signaling in metastases
(Matsuoka and Yashiro, 2014). The finding that ROCK2 and
DNA-PKcs inhibitors functioned cooperatively to suppress
migration and invasion suggests that pathways in addition to
Rho/Rac signalingmay contribute to DNA-PKcs-inducedmetas-
tasis (eg Wnt-b-catenin, TGFb), and it is intriguing to speculate
that DNA-PKcs forms a central signaling point modulating met-
astatic networks. The importance of DNA-PKcs inmetastatic for-
mation was confirmed in multiple in vivo models, as inhibition of
DNA-PKcs activity strongly delayed formation of metastases,(E) At time of sacrifice, metastases were documented ex vivo in the lungs and liver
lungs and livers assessed.
(F) CASP-NPK-YFP tumors were harvested for qPCR analysis with the indicated
Data are reported as mean ± SD. **p < 0.01. See also Figure S5.and crossover studies suggest that DNA-PKcs functions early
in establishment of metastatic lesions. Combined, these findings
provide comprehensive analysis of cancer-associated factors
regulated by DNA-PKcs and identify DNA-PKcs-mediated tran-
scriptional regulation as a driver of metastasis.
Finally, findings herein provide robust clinical evidence of
DNA-PKcs as promoting metastasis in human disease and as
a candidate biomarker to predict poor outcome. Despite recent
advances (Mitsiades et al., 2012), clinical biomarkers predicting
progression or therapeutic response in PCa are lacking. Ana-
lyses of clinical samples demonstrated that high DNA-PKcs
expression strongly correlates with decreased freedom from
recurrence, freedom from metastases, and survival, implicating
DNA-PKcs as a major driver of lethal cancer development.
Strikingly, DNA-PKcs held similar prognostic value to Gleason
score, underscoring its importance in disease progression.
Additionally, a second independent analysis revealed that
DNA-PKcs phosphorylation on residues associated with activa-
tion (Thr2609) and chromatin binding (Thr2609, Ser2612) is
highly enriched in metastatic versus treatment-naive tissues,
indicating that DNA-PKcs is highly active in metastatic PCa, in-
dependent of DNA damage markers. Although it was previously
thought that DNA-PKcs activation occurs only through Ku-medi-
ated binding to broken DNA, recent studies identified additionals by depicting fluorescence with the total number of metastatic nodules for the
transcripts set relative to Gapdh mRNA.







Figure 8. DNA-PKcs Is Associated Clinically with Disease Recurrence and Metastases
(A–C) Tumor samples were profiled for DNA-PKcs mRNA, which was split into high versus low by the 80th percentile for Kaplan Meier analysis.
(D–G) GSEA analyses showed enrichment of the AR pathway (D), MAZ (E), and SP1 (F) targets, and the focal adhesion pathway (G) in genes correlated to
DNA-PKcs.
(H) DNA-PKcs and histone H2AX phosphorylation were measured by mass spectrometry in organ confined, treatment-naive PCa and metastatic CRPC
tissues.
(legend continued on next page)
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mechanisms that contribute to DNA-PKcs activation, such as
interaction with factors including AKT, EGFR, CK2, and multiple
protein phosphatases (Douglas et al., 2001; Goodwin and Knud-
sen, 2014). Although future studies are required to determine
which (if any) of these mechanisms contribute to DNA-PKcs
activation in the context of transcription, the kinase activity
of DNA-PKcs is targetable, and DNA-PKcs inhibitors are
currently in clinical trials for advanced solid tumors, hematologic
malignancies, and metastases (http://www.clinicaltrials.gov,
NCT01353625). Because the development of metastases is
nearly universally lethal in solid tumors, the clinical value in tar-
geting DNA-PKcs for prevention of metastatic development in
multiple malignancies should be evaluated.
In sum, the studies herein reveal paradigms for DNA-PKcs
activity, unveil definitive transcriptional regulatory functions
that promote the development of lethal tumor phenotypes, and
nominate DNA-PKcs as a therapeutic target.
EXPERIMENTAL PROCEDURES
Tail Vein Assays
Mouse studies were performed with Thomas Jefferson University IACUC
approval. PC3-ML or 22Rv1 cells expressing luciferase were pre-treated for
48 hr with 1 mM NU7441 or DMSO. After 48 hr, 1 3 105 cells were seeded in
hormone-proficient media for viability studies and 5 3 105 cells in 100 ml
PBS were injected into the tail veins of 6-week-old SCID mice. Cell number
and viability were determined via trypan blue exclusion. Mice were treated
every 24 hr 5 days/week with 25 mg/kg NU7441 or control through intraperito-
neal (i.p.) injection. Tumor volume was monitored by i.p. injection of 150 ml
RediJect D-Luciferin followed by IVIS imaging, with tumor volume quantified
by Living Image Software. At day 31 of the PC3-ML study, three mice per
cohort were selected for crossover studies. Mice not selected continued orig-
inal treatment for an additional week. Crossover mice received new treatment
for 2 weeks prior to sacrifice. Average doubling time pre- and post-crossover
was determined using Td = (t2t1)*((ln2)/ (ln(q2/q1))).
Clinical Analyses
DNA-PKcs Expression
Tumor samples were obtained from Mayo Clinic using a case-cohort study
design to randomly sample 20% of patients for analysis, in addition to all in
whom metastases developed, from a cohort of 1,010 high-risk men who
underwent radical prostatectomy between 2000 and 2006, for a total cohort
of 232 patients as described (Karnes et al., 2013). Studies were approved by
the Mayo Clinic IRB and informed consent obtained from all subjects. DNA-
PKcs expression was profiled using Affymetrix Human Exon 1.0 ST arrays.
Expression data were normalized and summarized using the SCAN algorithm
(Karnes et al., 2013). Expression was split into high versus low by the 80th
percentile of DNA-PKcs expression. Gleason was split into high (8–10) versus
intermediate/low (%7). Kaplan Meier curves and p values were generated
using the log-rank test. Expression of other genes was correlated with DNA-
PKcs using Spearman’s correlation. Pre-ranked GSEA analyses were run
using Spearman’s rho and indicated pathways analyzed.
DNA-PKcs Phosphorylation
DNA-PKcs and H2AX phosphorylation were measured in organ-confined,
treatment-naive PCa and metastatic CRPC tissues (Drake et al., 2013).
Studies were approved by the UCLA IRB and informed consent obtained
from all subjects. Phosphopeptide enrichment was performed as previ-
ously described (Zimman et al., 2010) with minor modifications. Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was performed(I) DNA-PKcs modulates cancer-associated transcriptional networks, inducing
signaling pathways and suppressing expression of UGT enzymes known to affe
metastatic CRPC.
Data are reported as mean ± SD. ***p < 0.001, *p < 0.05. See also Figure S6 andusing a Q-Exactive mass spectrometer. MS/MS fragmentation spectra
were searched using Andromeda (Cox et al., 2011) against the Uniprot hu-
man reference proteome database with canonical and isoform sequences
(downloaded January 2012 from http://www.uniprot.org) and a reversed
decoy database with a false discovery rate <0.01. Search parameters
included N-terminal acetylation and oxidized methionine as variable modifi-
cations and carbamidomethyl cysteine as a fixed modification. Variable mod-
ifications included phosphorylated serine, threonine, or tyrosine (phospho
[STY]). In addition, group-specific parameters included maximum missed
cleavages of 2. Search scores are reported in Table S2. Quantitation was
performed using Skyline 2.6.0.6851 (Schilling et al., 2012). Prior to analysis,
redundant spectral libraries were generated from Proteome Discoverer
search results of the raw data files using the same Uniprot human reference
proteome database. Retention time filtering was used so that only scans
within 2 min of an MS/MS id were included. The precursor isotopic
import filter was set to include only the first isotopomer (M0) at a Skyline
resolution setting of 70,000. Reintegration of the peaks was performed
with mProphet to improve peak picking, with a scoring model based on
precursor mass error, identification, and co-elution count. Results were re-
ported as areas under the curve (AUC) for each peptide. AUC values were
compared across the treatment-naive PCa and metastatic CRPC for DNA-
PKcs and H2AX phosphopeptides. Relative fold changes for each phosphor-
esidue as determined by the average of treatment-naive and metastatic
CRPC tissues were plotted. To calculate significance, two-tailed t tests or
Mann-Whitney U tests were used for normally and non-normally distributed
phosphopeptide data.
For details on other experiments, please refer to the Supplemental Experi-
mental Procedures.
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The accession number for the microarray reported in this paper is GEO:
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